15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $53M | -$7M | 48.8% | -10.4% | -$14M | — | $15M |
| 2024 | $53M | $3M | 54.5% | 7.3% | $7M | — | $20M |
| 2023 | $65M | $8M | 64.9% | 16.0% | -$2M | — | $24M |
| 2022 | $48M | -$15M | 58.9% | -27.3% | -$26M | — | $17M |
| 2021 | $38M | -$28M | 57.4% | -53.4% | -$12M | — | $39M |
| 2020 | $63M | -$7M | 82.7% | 4.3% | -$27M | — | $18M |
| 2019 | $55M | -$18M | 80.1% | -19.6% | -$20M | — | $18M |
| 2018 | $34M | -$26M | 72.8% | -56.4% | -$8M | — | $38M |
| 2017 | $21M | -$83M | 19.0% | -163.8% | -$11M | — | $51M |
| 2016 | $9M | -$29M | 8.7% | -360.5% | -$33M | — | $63M |
| 2015 | $4M | $58M | 83.3% | -542.4% | -$25M | — | $76M |
| 2014 | $4M | -$30M | 82.1% | -810.6% | -$30M | $912000 | $55M |
| 2013 | $0 | -$28M | — | — | -$33M | $2M | $86M |
| 2012 | $35M | -$12M | 75.4% | -34.9% | -$1M | $5M | $52M |
| 2011 | $8M | -$37M | 17.2% | -435.6% | -$29M | $7M | $27M |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $34M | $18M | 87.8% | 62.7% | $21M | — | $41M |
| Dec '25 | $9M | -$6M | 49.4% | -51.1% | $2M | — | $15M |
| Sep '25 | $18M | $2M | 53.4% | 11.9% | -$4M | — | $14M |
| Jun '25 | $16M | $164000 | 62.5% | 7.5% | -$6M | — | $18M |
| Mar '25 | $10M | -$4M | 19.1% | -41.0% | -$5M | — | $19M |
| Dec '24 | $18M | $6M | 78.7% | 39.6% | $4M | — | $20M |
| Sep '24 | $18M | $3M | 53.4% | 22.2% | $4M | — | $27M |
| Jun '24 | $13M | -$2M | 29.8% | -18.0% | -$4M | — | $23M |
| Mar '24 | $4M | -$5M | 30.6% | -129.6% | $4M | — | $27M |
| Dec '23 | $10M | -$6M | 15.5% | -53.5% | $3M | — | $24M |
| Sep '23 | $10M | -$2M | 52.7% | -18.2% | -$7M | — | $20M |
| Jun '23 | $35M | $19M | 82.5% | 58.2% | $5M | — | $48M |
| Mar '23 | $10M | -$3M | 67.8% | -25.6% | -$3M | — | $33M |
| Dec '22 | $9M | -$4M | 72.2% | -29.0% | -$3M | — | $17M |
| Sep '22 | $14M | -$4M | 50.1% | -22.0% | -$9M | — | $11M |
| Jun '22 | $9M | -$5M | 53.3% | -63.1% | -$7M | — | $12M |
| Mar '22 | $16M | -$2M | 62.5% | -11.6% | -$6M | — | $17M |
| Dec '21 | $9M | -$7M | 63.2% | -66.7% | -$6M | — | $39M |
| Sep '21 | $12M | -$4M | 69.3% | -15.6% | -$2M | — | $11M |
| Jun '21 | $6M | -$11M | 26.4% | -142.6% | $6M | — | $34M |
How the market has priced PLX against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Protalix BioTherapeutics, Inc.'s revenue has declined 3.5% per year. These are computed facts, not advice.
As of FY2025, Protalix BioTherapeutics, Inc. reported — of total debt against $15M of cash.
In FY2025, gross margin was 48.8%, operating margin -10.4%, and net margin -12.5%.
As of Jun '26, Protalix BioTherapeutics, Inc. traded at a price-to-earnings ratio of about 49.2× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S have moved with the share price. These are computed facts, not advice.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.